인테그린 억제제를 사용한 간 질환의 조합 치료

본 발명은 간 질환 또는 장애를 예방하거나 지연시키거나 치료하기 위한 αVβ1 인테그린 억제제 및 적어도 1종의 추가 치료제를 포함하는 약제학적 조합물을 제공한다. 적어도 1종의 추가 치료제는 파르네소이드 X 수용체(FXR) 작용제일 수 있다. 예를 들어, 약제학적 조합물은 (S)-2-(4-메틸테트라하이드로-2H-피란-4-카복사미도)-9-(5,6,7,8-테트라하이드로-1,8-나프티리딘-2-일)노난산(화합물 1) 및 2-[3-({5-사이클로프로필-3-[2-(트리플루오로메톡시)페닐]-1,2-옥사졸-4-일}메톡시)-8-아자바이사이클로[3...

Full description

Saved in:
Bibliographic Details
Main Authors ANDERSON KRAIG, BAILEY CHRISTOPHER, COOPER NICOLE, BOSE AVIRUP, KIRKLAND SUSAN, REILLY MAUREEN, LEFTHERIS KATERINA, HULL JOHANNES, UKOMADU CHINWEIKE, GREENBAUM LINDA, CHA JACOB, TARSA PETER, FINKELSTEIN DARREN
Format Patent
LanguageKorean
Published 01.09.2022
Subjects
Online AccessGet full text

Cover

Loading…
Abstract 본 발명은 간 질환 또는 장애를 예방하거나 지연시키거나 치료하기 위한 αVβ1 인테그린 억제제 및 적어도 1종의 추가 치료제를 포함하는 약제학적 조합물을 제공한다. 적어도 1종의 추가 치료제는 파르네소이드 X 수용체(FXR) 작용제일 수 있다. 예를 들어, 약제학적 조합물은 (S)-2-(4-메틸테트라하이드로-2H-피란-4-카복사미도)-9-(5,6,7,8-테트라하이드로-1,8-나프티리딘-2-일)노난산(화합물 1) 및 2-[3-({5-사이클로프로필-3-[2-(트리플루오로메톡시)페닐]-1,2-옥사졸-4-일}메톡시)-8-아자바이사이클로[3.2.1]옥탄-8-일]-4-플루오로-1,3-벤조티아졸-6-카복실산(트로피펙소)을 포함한다. The invention provides a pharmaceutical combination including an αvβ1 integrin inhibitor and at least one additional therapeutic agent for preventing, delaying or treating liver diseases or disorders. The at least one additional therapeutic agent may be a farnesoid X receptor (FXR) agonist. For example, the pharmaceutical combination includes (S)-2-(4-methyltetrahydro-2H-pyran-4-carboxamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid (Compound 1) and 2-[3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1, 3-ben-zothiazole-6-carboxylic acid (tropifexor).
AbstractList 본 발명은 간 질환 또는 장애를 예방하거나 지연시키거나 치료하기 위한 αVβ1 인테그린 억제제 및 적어도 1종의 추가 치료제를 포함하는 약제학적 조합물을 제공한다. 적어도 1종의 추가 치료제는 파르네소이드 X 수용체(FXR) 작용제일 수 있다. 예를 들어, 약제학적 조합물은 (S)-2-(4-메틸테트라하이드로-2H-피란-4-카복사미도)-9-(5,6,7,8-테트라하이드로-1,8-나프티리딘-2-일)노난산(화합물 1) 및 2-[3-({5-사이클로프로필-3-[2-(트리플루오로메톡시)페닐]-1,2-옥사졸-4-일}메톡시)-8-아자바이사이클로[3.2.1]옥탄-8-일]-4-플루오로-1,3-벤조티아졸-6-카복실산(트로피펙소)을 포함한다. The invention provides a pharmaceutical combination including an αvβ1 integrin inhibitor and at least one additional therapeutic agent for preventing, delaying or treating liver diseases or disorders. The at least one additional therapeutic agent may be a farnesoid X receptor (FXR) agonist. For example, the pharmaceutical combination includes (S)-2-(4-methyltetrahydro-2H-pyran-4-carboxamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid (Compound 1) and 2-[3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1, 3-ben-zothiazole-6-carboxylic acid (tropifexor).
Author UKOMADU CHINWEIKE
CHA JACOB
KIRKLAND SUSAN
LEFTHERIS KATERINA
REILLY MAUREEN
TARSA PETER
BOSE AVIRUP
BAILEY CHRISTOPHER
ANDERSON KRAIG
GREENBAUM LINDA
FINKELSTEIN DARREN
HULL JOHANNES
COOPER NICOLE
Author_xml – fullname: ANDERSON KRAIG
– fullname: BAILEY CHRISTOPHER
– fullname: COOPER NICOLE
– fullname: BOSE AVIRUP
– fullname: KIRKLAND SUSAN
– fullname: REILLY MAUREEN
– fullname: LEFTHERIS KATERINA
– fullname: HULL JOHANNES
– fullname: UKOMADU CHINWEIKE
– fullname: GREENBAUM LINDA
– fullname: CHA JACOB
– fullname: TARSA PETER
– fullname: FINKELSTEIN DARREN
BookMark eNrjYmDJy89L5WSwfzN3x9vWnlfbd7xetkHhzbStbxbMAaLXS_covGla82bWyrdT5yi82tCi8GZ5x9uZM97MnaHwZuGGt1NXKrzZOeP14h4eBta0xJziVF4ozc2g7OYa4uyhm1qQH59aXJCYnJqXWhLvHWRkYGRkYGhkaGFs4WhMnCoAZAZFxA
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
ExternalDocumentID KR20220121838A
GroupedDBID EVB
ID FETCH-epo_espacenet_KR20220121838A3
IEDL.DBID EVB
IngestDate Fri Jul 19 12:58:30 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language Korean
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_KR20220121838A3
Notes Application Number: KR20227024756
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220901&DB=EPODOC&CC=KR&NR=20220121838A
ParticipantIDs epo_espacenet_KR20220121838A
PublicationCentury 2000
PublicationDate 20220901
PublicationDateYYYYMMDD 2022-09-01
PublicationDate_xml – month: 09
  year: 2022
  text: 20220901
  day: 01
PublicationDecade 2020
PublicationYear 2022
RelatedCompanies PLIANT THERAPEUTICS, INC
NOVARTIS AG
RelatedCompanies_xml – name: NOVARTIS AG
– name: PLIANT THERAPEUTICS, INC
Score 3.3960671
Snippet 본 발명은 간 질환 또는 장애를 예방하거나 지연시키거나 치료하기 위한 αVβ1 인테그린 억제제 및 적어도 1종의 추가 치료제를 포함하는 약제학적 조합물을 제공한다. 적어도 1종의 추가 치료제는 파르네소이드 X 수용체(FXR) 작용제일 수 있다. 예를 들어, 약제학적 조합물은...
SourceID epo
SourceType Open Access Repository
SubjectTerms HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Title 인테그린 억제제를 사용한 간 질환의 조합 치료
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220901&DB=EPODOC&locale=&CC=KR&NR=20220121838A
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwY2BQMTdLA2Yj82TdRCNgd9XEMNlA1zLVwlIXmJVMkkwtLCzNwLco-PqZeYSaeEWYRjAx5MD2woDPCS0HH44IzFHJwPxeAi6vCxCDWC7gtZXF-kmZQKF8e7cQWxc1aO_YyMgAWL-puTjZugb4u_g7qzk723oHqfkFQeQMQe0BC0dmBlZgQ9oCtADQNcwJtC-lALlScRNkYAsAmpdXIsTAlJ0vzMDpDLt7TZiBwxc65Q1kQnNfsQiD_Zu5O9629rzavuP1sg0Kb6ZtfbNgDhC9XrpH4U3TmjezVr6dOkfh1YYWhTfLO97OnPFm7gyFNws3vJ26UuHNzhmvF_eIMii7uYY4e-gCXRIP93i8dxCys43FGFjy8vNSJRgUzFPTLJMTzc1Ap68D2ztmFsmJoKo21TDZ0NgsOTFNkkEGn0lS-KWlGbhAXMhKKhkGlpKi0lRZYNVbkiQHDjEAFquY8g
link.rule.ids 230,309,786,891,25585,76894
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwY2BQMTdLA2Yj82TdRCNgd9XEMNlA1zLVwlIXmJVMkkwtLCzNwLco-PqZeYSaeEWYRjAx5MD2woDPCS0HH44IzFHJwPxeAi6vCxCDWC7gtZXF-kmZQKF8e7cQWxc1aO_YyMgAWL-puTjZugb4u_g7qzk723oHqfkFQeQMQe0BC0dmBlZgI9sSdNK-a5gTaF9KAXKl4ibIwBYANC-vRIiBKTtfmIHTGXb3mjADhy90yhvIhOa-YhEG-zdzd7xt7Xm1fcfrZRsU3kzb-mbBHCB6vXSPwpumNW9mrXw7dY7Cqw0tCm-Wd7ydOePN3BkKbxZueDt1pcKbnTNeL-4RZVB2cw1x9tAFuiQe7vF47yBkZxuLMbDk5eelSjAomKemWSYnmpuBTl8HtnfMLJITQVVtqmGyobFZcmKaJIMMPpOk8EvLM3B6hPj6xPt4-nlLM3CBpCCrqmQYWEqKSlNlgdVwSZIcOPQAbr2b5Q
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=%EC%9D%B8%ED%85%8C%EA%B7%B8%EB%A6%B0+%EC%96%B5%EC%A0%9C%EC%A0%9C%EB%A5%BC+%EC%82%AC%EC%9A%A9%ED%95%9C+%EA%B0%84+%EC%A7%88%ED%99%98%EC%9D%98+%EC%A1%B0%ED%95%A9+%EC%B9%98%EB%A3%8C&rft.inventor=ANDERSON+KRAIG&rft.inventor=BAILEY+CHRISTOPHER&rft.inventor=COOPER+NICOLE&rft.inventor=BOSE+AVIRUP&rft.inventor=KIRKLAND+SUSAN&rft.inventor=REILLY+MAUREEN&rft.inventor=LEFTHERIS+KATERINA&rft.inventor=HULL+JOHANNES&rft.inventor=UKOMADU+CHINWEIKE&rft.inventor=GREENBAUM+LINDA&rft.inventor=CHA+JACOB&rft.inventor=TARSA+PETER&rft.inventor=FINKELSTEIN+DARREN&rft.date=2022-09-01&rft.externalDBID=A&rft.externalDocID=KR20220121838A